Clinical Pharmacology and Therapeutics 1999: Vol 65 Index

13 Pages·1999·3.2 MB·English

Index to volume 65
Author index
Blum RA (see Chakraborty et al). 1999;65:304-18
Bochner F (see Dyer et al). 1999:65:685-94
Aarons L (see Gupta et al). 1999;65:672-84 Branch RA (see Bluhm et al). 1999:65:598-605
Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns Breil M (see Sanquer et al). 1999:65:640-8
GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo Bremer F (see Teg tt al). 1999;65:50-7
1999:65:465-72 Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy
Abernethy DR (see Jones et al). 1999;65:408-12 KC, Aweeka FT. Pharmacokinetics of cidofor
Abernethy DR (see Schulman et al). 1999;65:593-7 ciency and in continuous ambulato1
Abolfathi Z (see Yacobi et al). 1999;65:389-94 hemodialysis. 1999;65:21-8
Adcock S (see Schwartz et al). 1999:65:653-60 Brune K (Sée Tegeder et al). 1999:65
Addison RS (see Gross et al). 1999:65:395-401 Brune K (see Tegeder et al). 1999:65
Adedoyin A (see Bluhm et al). 1999;65:598-605 Brune K (see Tegeder et al). 1999;65
Agostoni P (see Guazzi et al). 1999;65:319-27 Budde K (see Miick et al). 1999;65:251
Agundez JA (see Martinez et al). 1999:65:369-76 Buemi M, Allegra A, Corica F, Rt
AlbetC (see Martinez et al). 1999;65:369-76 Giacobbe MS, Romeo A, Frisina N
Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, tion on blood bc/-2 concentrations 1 vith immunoglobulin
Schwilden H, Schiittler J. The effect of age on the pharmacokinetics \ nephropathy. 1999;65:649-52
and pharmacodynamics of midazolam. 1999;65:630-9 Bukowski R (see Rakhit et al). 1999:65:615-29
Aleman C (see Mas et al). 1999;65:439-47 Bulitta J (see Kinzig-Schippers et al). 1999;65:2K6I2.-77A4
Alisi C (see Buemi et al). 1999;65:649-52
Allegra A (see Buemi et al). 1999;65:649-52
Andrawis NS (see Jones et al). 1999;65:408-12
Aravind MK (see Kauffman et al). 1999;65:382-8
Ariyoshi N (see Tateishi et al). 1999;65:570-5 aracoY (see Sviri et al). 1999;65:275
Arvieux C (see Michelet et al). 1999;65:661-71 ‘arcas AJ, Garcia-Satué JL, Zapater ta J. Tobramycin
Astier A (see Sanquer et al). 1999;65:640-8 penetration into epithelial lining ft patients v nonia
Atkinson AJ (see Shepherd and Atkinson). 1999;65:355-6 1999:65:245-50
Carrillo JA (see Martinez et al). 1999;65:369-76
(Commentary )
Cartier F (see Michelet et al). 1999;65:661-71
Aweeka FT (see Brody et al). 1999;65:21-8
\ziz M (see Massien et al). 1999;65:448-59 Carvajal DM (see Rakhit et al). 1999;65:615-29
Cassel W (see Heitmann et al). 1999;65:328-35
B Castano G (see Mas et al). 1999:65:439-47
Chakraborty A, Blum RA, Cutler DL, Jusko WJ. Pharm:
Bachmann KA (see Schwartz et al). 1999;65:653-60 dynamic interactions of interleukin-10 and prednisone in
Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, volunteers. 1999:65:304-18
Hendrix CW, Flexner C. The effects of rifampin and rifabutin on the ‘halon S, Bedarida GV, Moreno H, Tejura B
pharmacokinetics and pharmacodynamics of a combination oral Blaschke TF. Inhibition of angiotensin-conve
contraceptive. 1999;65:428-38 hand veins. 1999:65:58-65
Barennes H (see Pussard et al). 1999:65:500-10 halon S, Moreno H, Hoffman BB, Blaschke
Baron C (see Sanquer et al). 1999;65:640-8 verting enzyme inhibition improves v
Bauer S (see Miick et al). 1999;65:251-61 in chronic smokers. 1999:65:295-303
Bazin C (see Michelet et al). 1999:65:661-71 ‘han CC (see Schwartz et al). 1999:65:653-60
Beaver WT (see Wideman et al). 1999:65:66-76 “*hauvin JP (see Michelet et al). 1999:65:661
Bedarida GV (see Chalon et al). 1999:65:58-65 heng CL (see Huang et al). 1999;65:402-7
Beerahee M (see Hussein et al). 1999:65:1-9 da M (see Tateishi et al). 1999:65:570-5
Beglinger C (see Drewe et al). 1999;65:413-9 ‘horazyczew ski J (see Gros et al 1999:65:545-51
Bellisant E (see Michelet et al). 1999:65:661-71 ‘huang SK (see Huang et al). 1999;65:402-7
Benitez J (see Martinez et al). 1999;65:369-76 ‘lavier F (see Pussard et al). 1999:65:500-10
Benovic JL (see Gros et al). 1999;65:545-51 ohen RA (see Schwartz et al). 1999;65:653-60
Berndt A (see Scwarz et al). 1999:65:283-29 olaizzi JL (see Yacobi et al). 1999:65:389-94
Bickel U (see Heitmann et al). 1999:65:328-35 ‘olburn W (see Scheffler et al). 1999:65:483-90
Bjornsson T (see McCrea et al). 1999:65:348-52 ‘olice G (see Hussein et al). 1999;65:1-9
Blaschke TF (see Chalon et al). 1999:65:58-65 ‘oresh J (see Barditch-Crovo et al). 1999:65:423-38
Blaschke TF (see Chalon et al). 1999;65:295-303 ‘orica F (see Buemi et al). 1999:65:649-5
Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of ‘ribb A (see McCrea et al). 1994;65:348-52
dapsone toxicity in patients with inflammatory dermatoses: activity ‘undy KC (see Brody et al). 1999:65:21-8
of acetylation and hydroxylation of dapsone as risk factors ‘utler DL (see Chakraborty et al). 1999:65:304-18
1999:65:598-605 RA‘AAz RajAa-RBAulRsaA RGA R(sRee ARGaAwRroAnRsAkaA-RSzAkDlaLrAzD et al). 1999:65:562-9
D
eeeeeee e
January, pp. 1-116; February, pp. 117-234; March, pp. 235-354; April,
pp. 355-464; May, pp. 465-592; June, pp. 593-716. Index to the Dallaire BK (see de Jonge et al). 1999;65:491-9
ASCPT meeting abstracts is located in the February issue Dallob A (see Ehrich et al). 1999:65:336-47
CLINICAL PHARMACOLOGY & THERAPEUTICS JUNE 1999 705
1900
999-65
1999-65:630-9

CLINICAL PHARMACOLOGY & THERAPEUTICS
708 Author index JUNE 1999
McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Peter JH (see Heitmann et al). 1999;65:328-35
Waldman S, Bjornsson T, Speilberg S, Goldberg MR. Phenotypic and Pettinato G (see Buemi et al). 1999;65:649-52
genotypic investigations of a healthy volunteer deficient in the con Pontigas V (see Mas et al). 1999;65:439-47
version of losartan to its active metabolite E-3174. 1999;65:348-52 Porras A (see Ehrich et al). 1999:65:336-4
Mehlisch DR (see Ehrich et al). 1999:65:336-47 Presky DH (see Rakhit et al). 1999;65:615-29
Mehta R (see Yacobi et al). 1999:65:389-94 Proost JH. Do computational results depend on PC processors?
Meller S (see Tegeder et al). 1999;65:357-68 1999:65:460 (Letter)
Melzi G (see Guazzi et al). 1999:65:314 9-2 Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M,
Ménard J (see Massien et al). 1999:65:448 Granic G, Verdier F. Quinine disposition in globally malnourishea
Menelaou A (see¢ Dyer et al). 1999:65:685-94 children with cerebral malaria. 1999;65:500-10
Michelet C, Beilisant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F,
, Renard I, Sebille V, Chauvin JP, Dohin E, Cartier F. Safety
and efficacy of retonavir and saquinavir in combination with zidovu R
and lamivudine. 1999;65:661-71
ra K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima | Raffi F (see Michelet et al). 1999;65:661-71
Otani K, Kaneko S, Inoue Y. Effects 1e CYP2D6*/0 allele on the Rakhit A, Yeon MM, Ferrante J, Fettner S$, Nadeau R, Motzer R
Steady-state plasma concentrations of haloperidol and reduced Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J,
haloperidol in Japanese patients with schizophrenia. 1999;65:291-4 Gately MK. Down-regulation of the pharmacokinetic-pharmacody-
Mizorogi Y (see Tateishi et al). 1999;65:570-5 namic response to interleukin-12 during long-term administration to
Mohamed MHN (see Lima et al). 1999;65:519-25 patients with renal cell carcinoma and evaluation of the mechanism
Moreno H (see Chalon et al). 1999:65:58-65 of this “adaptive response” in mice. 1999;65:615-29
Moreno H (see Chalon et al). 1999:65:295-303 Ramirez J (see lyer et al). 1999;65:576-82
MoritzC (see Schwartz et al). 1999:65:653-60 Ratain MJ (see lyer et al). 1999;65:576-82
Moros D (see Yacobi et al). 1999:65:389-94 Rathore SS (see Schulman et al). 1999:65:593
Morris E (see Wideman et al 1999-65:66-76 Rei:d enberg : MM. New headings for the table of contents. 1999:65:2
Mortell MA (see lyet 1999-65:576~ -8 )
MottetC (see Drewe 1999-65:413-9 Renard I (see Michelet et al). 1999;65:661
Motzer R (see Rakhit et al). 1999;65:615 Rider MJ (see Tschen et al). 1999:65:526-32
Miick W, Mai I, Fritsche | Riendeau D (see Ehrich et al). 1999;65:336-4
Baue Rocco LE (see Barditch-Crovo et al). 1999;65:423-38
cerivastatin systemic exposure after single and multiple dosing in Rohde G (see Miick et al). 1999;65:251-61
cyclosporine-treated kidney transplant recipients. 1999;65:251-61 Romeo A (see Buemi et al). 1999:65:649
Muir KT (see Hermann et al 1999:65:511-8 Roots I (see Miick et al). 1999:65:251-61
Mukhopadhyay S 1999:65:653-60 see Buemi et al). 1999:65:649-52
Muth-SelbachU ( -9eder et al). 1999:65:357-68 ault A (see Michelet et al). 1999:65:661-71
Muth-Selbach U (s¢ »geder et al). 1999:65:533-44 Rushmore T (see McCrea et al). 1999:65:348-52
Riising G (see Kinzig-Schippers et al). 1999:65:262-74
Riising G (see Tegeder et al). 1999:65:357-68
15.99
tal). 1999-65-29]
999-65:-606 19909-65:-990.39
} P cede et al 000-65-5( 1999-65:500-10
umayer HH (see il). 1999:65 Dhamane D, Astier A, Lang
1en PJ, Kantola Kivist6 KT lase activity aft
ista II [t eraction. 1999:65:583 (1L et vith mycophenolate mofetil. 1999;65:640-8
uvonen PJ (see Villikka et al). 1999;65 see Gupta et al). 1999;65:672-84
shimoto M (see Furuta et al 999-65°559 Scheffler MR, Colburn W, Ko
not alter estrogen-progesteron
1999:65:2
1999-65:- 14
999-65:2 al). 1999:65:237-44
1999-65:357 DR, Rathore SS, Woosley RI
1999-65:283 manufacture! communication in the information
1999-65:552-61 1999-65:593
999-65:369 1999-65:630-9
ea et al | 1999-65-34 +O Mukhopadhyay S, McBride K, Jones TM,
al 1999:65:500-10 S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA,
1999-65:291-4 vidson MH, Bachmann KA, Gertz BJ. Cyclooxy ase-2 inhibi
] 1999:65:5 ion by rofecoxib reverses naturally occurring fever in humans
1999:65:653-60
Schwilden H (see Albrecht et al). 1999;65:630-9
P Scwarz UI, Gramatté T, Krappweis J, Berndt A, Oerte! R, von Richter
O, Kirch W. Unexpected effect of verapamil on oral bioavailability
\ message from the President: The Centennial ASCPT meet of the B-blocker talinolol in humans. 1999;65:283-290
ng—Come to San Antonio, March 18-20, 1999. 1999:65:80 Sebille V (see Michelet et al). 1999;65:661-71
Penzel T (see Heitmanent al). 1999:65:328-35 Seibold JR (see Ehriect hal) . 1999:65:336
PHARMACOLOGY &
65, NUMBER 6 Author index 709
Self TH (see Lima et al). 1999;65:519-25
9
Sheiner LB (see Gupta et al). 1999;65:6
Shenfield GM (see Gross et al). 1999:65 395-401 Van Hecken A (see Ehrich et a 199-65
Shepherd AMM, Atkinson AJ. Report from the American Board Vega JM (see Tobert et al 999-65:583 (I
Clinical Pharmacology. 1999;65:355 6 (Commentary Pussard et al). 1999;65:500
Shin JG (see Ko et al). 1999:65:606-14 de Jonge et al). 1999;65:49
Shin SG (see Ko et al). 1999:65:606-14 Vesterqvist O (see Massien et al). 1999-65
Shpizen S (see Sviri et al). 1999;65 27—e 5 On Villikka K, Kivist6 KT, Neuvonen PJ. The
Sieber CC (see Drewe et ual l). 1999;6 5:413-9 t of oral a
Somogyi AA (see Dyer et al). 1999:65:685-94 Hussein
Sérgel F (see Kinzig-Schippers et al). 1999;65:262 é
SoérgelF (see Teged t al 1999-65:357-68
Sparreboom A (s¢ e et al). 1999;65:491-9
Speilber S (see McCrea et al 1999-65:348-52
Suzuki A (see Mihara et al). 1999;65:291-4
Sviri S, Shpizen S, Leiersdorf E, Levy M, CaracoY . Pheno 1900-65-24
typic analysis of CYP2C19 in the Je Israel 100-465
1999-65:275-82 - 199-65
99-65
HAalSesic Cll ica
1999-65:552 1 postoperative pain it
e Gros et al). 1999:65:545-5 1 ilkinsoVnL (see Rakhit et al 999:65
hida M, Ariyoshi N, Mizor ilson DI ee ree t ; 999-65
> CYP2D6 gene in relat
I to dextromet
9909-65-57
Subject index
Analgesia
Characterization of rofecoxib as a cyclooxygenase-2 isoform
Acetylation inhibitor and demonstration of analgesia in the dental pain model
patients with inflammatory der (Ehrich et al). 1999:65:336-47
activity of acetylation and hydroxylation of dapsone as Analgesics, non-narcotic
(Bluhm et al). 1999:65:598-605 Analgesic efficacy of a combination of hydrocodone with ibuprofen
yetween acetylation polymorphism and risk of atopic in postoperative pain (Wideman et al). 1999;65:66-76
liseases (Gawrodanska-Szkla 1999:65:562-9 Analgesics, opioid
Acid-base equilibrium Analgesic efficacy of a combination of hydrocodone with ibuprofen
Cryrp zC/Y genotype status al t of omeprazole on intragastric in postoperative pain (Wideman et al). 1999;65:66-76
pH in humans (Furuta et ¢ 1999:65:552-61
Ancestim
Administration, topical
Ancestim (USAN List No. 414). 1999;65:462
Application of microdialysis for the determination of muscle and
Anecortave acetate
subcutaneous tissue concentrations after oral and topical ibupro
Anecortave acetate (USAN List No. 415). 1999;65:592
en administration (Tegeder et al). 1999;65:357-68
A ngiotensin-converting enzyme inhibitors
Adrenergic beta blockers
Angiotensin-converting enzyme inhibition facilitates alveolar-capil
Unexpectc bioavailability of the B lary gas transfer and improves ventilation-perfusion coupling in
1999-65:283-290
patients with left ventricular dysfunction (Guazzi et al). 1999;65
319-27
ramipril on sympathetic nervous system function in
al). 1999:65:420-7 Angiotensin-converting enzyme inhibition improves venous
Age factors endothelial dysfunction in chronic smokers (Chalon et al). 1999;
The effect of age on the pharmacokinetics and pharmacodynamics 65:295-303
of midazolam (Albrecht et al). 1999;65:630-9 Inhibition of angiotensin-converting enzyme in human hand veins
Ag ranulocytosis (Chalon et al). 1999:65:58-65
Phe cytotoxicity of clozapine metabolites: implications for predicting Pharmacodynamic effects of dual neutral endopeptidase
cloZapine ed agranulocytosis (Tschen et al). 1999:65:526-32 angiotensin-converting enzyme inhibition versus angiotensin
Albuterol converting enzyme inhibition in humans (Massien et al). 1999;
polymorphisms of the {5,-adrenergic receptor on 65:448-59
chodilator pharmacodynamics (Lima et al). 1999; Aniline compounds
Mixed-effects modeling of the pharmacodynamic response to the
calcimimetic agent R-568 (Lalonde et al). 1999;65:40-9
USAN List No. 416). 1999:65:697 Arzoxifene hydrochloride
AAliy notriptan malate Arzoxifene hydrochloride (USAN List No. 416). 1999;65:700
Almotriptan malate (USAN List No. 416). 1999:65:697 Avasimibe
American Board of Clinical Pharmacy Avasimibe (USAN List No. 414). 1999:65:462
Report from the American Board of Clinical Pharmacology
Shepherd and Atkinson). 1999:65:355-6 (Commentary
American Society for Clinical and Pharmacology and Therapeutics B
Abstracts of annual meeting. 1999;65:117-234
Election of Officers and Committe Chairpersons for 1999-2000 bel-2. see Proto-oncogene proteins c-bel-2
1999:65:695
Bexarotene
program. 1999:65:80-116
Bexarotene (USAN List No. 414). 1999:65:462
ge from the Membership Committee Chair (Jones)
Biological availability
999:65:586-9
Unexpected effec verapamil on oral bioavailability of the
from the SI > Centennial ASCPT meeting
1999 (Peck). 1999:65:80 (-blocker talinolol in humans (Schwarz et al). 1999:65:283-290
Blacks
n Committee Chairperson
Impaired endothelial-dependent forearm vascular relaxation in black
ission of abstracts for the 2000 annual meeting (Carruthers
Americans (Jones et al). 1999;65:408-12
1999:65:696
Future meeting dates and sites of the ASCPT. 1999:65:696 Blood pressure
9-Amnocamptothecin Does short-term treatment with modafinil affect blood pressure in
Clinical pharmacokinetics of encapsulated oral 9-aminocamp patients with obstructive sleep apnea? (Heitmann et al). 1999;
65:328-35
tothecin in plasma and saliva (de Jonge et al). 1999;65:491-9
Amoxicillin sodium Impaired endothelial-dependent forearm vascular relaxation in black
Amoxicillin sodium (USAN List No. 415). 1999:65:592 Americans (Jones et al). 1999;65:408-12
Amprenavir Bradykinin
Amprenavir (USAN No. 416). 1999:65:702 Inhibition of angiotensin-converting enzyme in human hand veins
(Chalon et al). 1999;65:58-65
Bronchodilator agents
January, pp. 1-116; February, i pp. 11 ch, pp. 235-354; April Impact of genetic polymorphisms of the f>-adrenergic receptor on
pp. 355-464; May, pp. 465-592; June 593-716. Index to the albuterol bronchodilator pharmacodynamics (Lima et al). 1999;
ASCPT meeting abstracts is located in the February issue 65:519-25
710 JUNE 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS
Cyclosporine
TD
‘alcium
Mixed-effects modeling of
cimi. metic agentnt RK -508 ‘
‘alcium channel blockers
alfactant
Calfactant (USAN List
arbamazepine
P45( e CYPIA2 (K
65 329.904 Cytochrome P450 CYP3A
arcinoma, renal cell
Down-regulatio
Cytochrome P450 CYP3A4
‘aspofungin acetate I )
Caspofun in acetal USAN I
‘erebral malaria. see Malaria, cerebral
Cytochrome P450 CYP2C19
‘erivastatin YP2C19 genotype stat
H
Cytochrome P450 CYP2D6
Cri dD
hinese
Pha
‘isapride
Influence of
1). 1999-65
‘larithromycin
( hrome (Desta et 99
linical Pharmacology and Therapeutics
linical pharmacy
S| Cytosine
lozapine
‘olesevelam hydrochloride
Colese
‘ommentaries
Commentaries Dapsone
ommunication )
R ‘
NCE i lid
tion age (Schuln
S (Db
‘omputers. see Microcomputers Darbufelone mesylate
ontinuous ambulatory peritoneal dialysis. Peritoneal dialysis, ID YI
continuous ambulatory Depreotide
‘ontraceptives, oral Dept t LIS + \ N\I ] st \ N
Dermatoses. Skin diseases
pharmacodyn Desloratadine
Barditch-Crovo Picclowimaiers SAN
‘oronary disease Dextromethorphan
Effec> ts of pYolli icosan'o l 1 iniy p+a9 tien*y ts witith h txt ype
and additional coronary risk factors (Mas
yclooxygenase. see Prostaglandin endoperoxide synthase
eneearr ee
CLINICAL PHARMACOLOGY & THERAPEUTICS
712 Subject index JUNE 1999
Diclofenac Phenotypic and genotypic investigations of a healthy volunteer defi-
Comparison of inhibitory effects of meloxicam and diclofenac on cient in the conversion of losartan to its active metabolite E-3174
human thromboxane biosynthesis after single doses and a steady (McCrea et al). 1999;65:348-52
state (Tegeder et al). 1999;65:533-44 Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli
Drospireone population (Sviri et al). 1999;65:275-82
Drospireone (USAN List No. 412). 1999;65:79 Glomerulonephritis, IGA
Drug evaluation Effects of lisinopril administration on blood bc/-2 concentrations in
Regulating manufacturer-affiliated communication in the informa patients with immunoglobulin A nephropathy (Buemi et al)
ion age (Schulman et al). 1999;65:593 1999:65:649-52
Drug interactions G-proteins
channel blocker-simvastatin interaction (Tobert et al) G-protein-coupled receptor kinase expression in hypertension (Gros
Neuvonen et al) (Reply). 1999:65:583 et al). 1999;65:545-51
immunodynamic interactions of interleukin-10 and pred Grapefruit juice
>in healthy volunteers (Chakraborty et al). 1999;65:304-18 6’,7’-Dihydroxybergamottin in grapefruit juice and Seville orange
Drug metabolism juice: effects on cyclosporine disposition, enterocyte CYP3A4, P
\tiomer-selective pharmacokinetics and metabolism of ketorolac glycoprotein (Edwards et al). 1999;65:237-44
hildren (Kauffman et al). 1999:65:382-8 Influence of grapefruit juice on cisapride pharmacokinetics (Gross et
al). 1999;65:395-401
Guest reviewers
Guest reviewers. 1999:65:461
Ecopipam hydrochloride
Ecopipam hydrochloride (USAN List No. 416). 1999;65:700
{mitefur
Emitefur (USAN List No. 416). 1999:65:701 Haloperidol
‘nalaprilat Effects of the CYP2D6*/0 allele on the steady -State plasma concen
Inhibition of angiotensin-converting enzyme in human hand veins trations of haloperidol and reduced haloperidol in Japanese
(Chalon et al). 1999:65:58-65 patients with schizophrenia (Mihara et al). 1999;65:291-4
‘nantiomers. see Stereoisomerism Hand
endothelium Inhibition of angiotensin-converting enzyme in human hand veins
Angiotensin-converting enzyme inhibition improves venous (Chalon et al). 1999:65:58-65
in chronic smokers (Chalon et al). 1999; Hefilcon A
Hefilcon A (USAN List No. 415). 1999;65:591
Hemodialysis
Pharmacokinetics of cidofovir in renal insufficiency and in continu
ous ambulatory peritoneal dialysis or high-flux hemodialysis
enoxacin with the human cytochrome (Brody et al). 1999:65:21-8
hippers et al). 1999;65:262-74 Hemofiltration
Pharmacokinetics of meropenem in critically ill patients with acute
idomide does not alter estrogen progesterone hormone renal failure undergoing continuous venovenous hemofiltratior
yharmacokinetics (Scheffler et al). 1999:65:483-90 (Tegeder et al). 1999:65:50-7
Hilafilcon A
Hilafilcon A (USAN List No. 415). 1999;65:591
Histamine agonists
FDA. see United States Federal Drug Administration Comparative in vitro and in vivo inhibition of cytochrome P4
Flibanserin CYP1A2, CYP2D6, and CYP3A by H
Flibanserin (USAN List No. 416). 1999:65:700 Martinez et al). 1999;65:369-76
Fodipir Hydrocodone
Fodipir (USAN List No. 416). 1999:65:699 Analgesic efficacy of a combination of hydrocodone with ibuprofer
Forearm in postoperative pain (Wideman et al). 1999;65:66-76
Impaired endothelial-dependent forearm vascular relaxation in black Hydroxylation
Americans (Jones et al). 1999:65:408-12 Development of dapsone toxicity in patients with inflammatory der
Frovatriptan succinate toses: activity of acetylation and hydroxylation of dapsone as
Frovatriptan succinate (USAN List ». 416). 1999:65:698 risk factors (Bluhm et al). 1999;65:598-605
Hypercholesterolemia
G Effects of policosanol in patients with type II hypercholesterolemia
and additional coronary risk factors (Mas et al). 1999:65:439-47
Ganaxolone
Hypertension
Ganaxolone (USAN List No. 416). 1999;65:702 The effects of ramipril on sympathetic nervous system function in
Gastric acidity determination
older patients with hypertension (Lee et al). 1999;65:420-7
CYP2C19 genotype status and effect of omeprazole on intragastric
G-protein-coupled receptor kinase expression in hypertension (Gros
DH in humans (Furut 1999:65:552-61 et al). 1999;65:545-51
Genotype
Impaired endothelial-dependent forearm vascular relaxation in black
CYP2C/9 genotype status at ymeprazole on intragastric
Americans (Jones et al). 1999:65:408-12
pH in humans (Furuta et al). 1999:65:552-61
Pharmacokinetics of metoprolol enantiomers in Chinese subjects of
major CYP2D6 genotypes (Huang et al). 1999:65:402-7
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of Ibuprofen
irinotecan) and bilirubin glucuronidation in human liver tissue with Analgesic efficacy of a combination of hydrocodone with ibuprofen
UGTIAI1 promoter polymorphism (Iyer et al). 1999;65:576-82 in postoperative pain (Wideman et al). 1999;65:66-76
CLINICAL PHARMACOLOGY
VOLUMI 65, NUMBER 6 Subject inWdile x
Application of microdialysis for the determination of muscle and
subcutaneous tissue concentrations after oral and topica
fen administration ( egeder et al). 1999:65:357-68 amivudine
IGA glomerulonephritis. see Glomerulonephritis, IGA Safety and letticacy of
Immunoglobulin A nephropathy. s< Glomerulonephritis, IGA zidovudine an+d |l ami ‘
Immunosuppressive agents anreotide
Systemic and intestinal pharmacokinetics of methotrexate in patients UVose-dependent gastrointe
with inflammatory bowel disease (Egan et al). 1999;65 19.39
ansoprazole
Information dissemination see Communication
Theophylline pharmacokineti
Injections, intravenous
The effect of rifampin on the pharmacokinetics of o1 CYP2C19 poor metabolizers (K yet al 199-65: 606 4
eft ventricular dysfunction. s Ventricular dysfunction, left
venous ondanestron (Villikka et al) 1999-65:377-81
etters
Inosine monophosphate dehydrogenase
Do computational results det PC
Induction of inosine monophosphate dehydrogenase activity 1999-65:460 (1 ettte
long-term treatment with mycophI enolate mofetil (Sanqu|e r et isinopril
1999-65:640-8 Effects of
Interleukin-10 patients
Pharmacoimmunodynamic interactions of interleukin-10 and p 1999-65:649-5
nisone in heal 1y volunteers (Chakraborty et al). 1999:65:304 18 Jiver
Interleukin-12 Phenotype-genotype corr
Down-regulation pharmacokinetic-pharmacodynamic rinotecan) and bilirubin gluct
response to during long-term administration promoter polymorpt
patients with 1 ‘nal I al). 1999:65:615-29 Lopinavir
Irinotecan [ (USAN No +16
Phe notype g type correlation of in vitro SN-38 active metabolite of Losartan
irinotecan) and bili ubin glucuronidation in human liver t uc NV id genotypic
UGTIAI omotetrel polymorphism (Iyer et al). 1999;65:576-82 the conver s10n
Israel 1999-65
Phenotypic-genotypic analysis of CYP2¢
population (Sviri et il). 1999:65:27 5-82
Malaria, cerebral
Quin
ilaria (Puss 199-65:500
Japanese
Malnourishment. s< Nutrition disorders
Analysis of the in relation to dextron Meloxicam
demethy lati 1 Japan ese population
1999:65:570-5
Methotrexate
Syst eCmic al
Metoprolol
Ketorolac PI arm
Enantiomer ective
in children (Kauffman
Kidney failure, acute
Pha irmacokinetics of merope
renal failure undergoing continuous yatients W
Microcomputers
(Tegeder et al). 1999;65:50-7
Dx
Kidney failure, chronic
1999-65:4
Pharmacokinetics of cidofovir in renal insufficiency and Microdialysis
Ous ambulatory peritoneal dialysis or high-flux he Application o
(Brody et al). 1999;65:21 Q
suBCULANeCOUS
Kidney transplantation
fen admini
Increase in cerivastatin systemic exposure Midazolam
dosing in cyclosporine-treated kidney transplant recipient
et al) 1999:65:251-61 ot n id
Induction of inosine monophosphate dehydrogenase acti\ Modafinil
long-term treatment with mycophenolatet e mot etil (Sanquer Does short erm treatment wit
1999:65:640-8 with obstructive sleep apnea
XAPEUTICS
l + Sulyect inde NE 1999
Muscle tonus Phenotypic and genotypic investigations of a healthy volunteer defi
Pharmacokinetics and pharma namics of SB 209670, cient in the conversion of losartan to its active metabolite E-31
McCrea et al). 1999:65:348-52
ascular tone (Freec Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli
Mycophenolate mofetil population (Sviri et al). 1999;65:275-82
nosine monopt pnate Gd ydrogenase Pimozide
ofetil (Sanquer et al Effect of clarithromycin on the pharmacokinetics and pharmacody
namics of pimozide in healthy poor and extensive metabolizers of
cytochrome (Desta et al). 1999;65:10-20
Plasma
Clinical pharmacokinetics of encapsulated oral 9-aminocamp
tothecin in plasma and saliva (de Jonge et al). 1999;65:491-9
Nitric-oxide synthase Steady-state pharmacokinetics and pharmacodynamics in
1etics of the ase inhibitor L-NY-methy mTeCtU ladone maintenance patients: comparison of holders versus
iloride in patients with septic shock (Hussein et nonholders and concentration-effect relationships (Dyer et al)
1999-65:1-9 685-94
Nutrition disorders Pleconaril
Ou > disposition ir Pleconaril (USAN List No. 412). 1999:65:79
(Pussal Pneumonia
Tobramycin penetration into epi lining fluid of patients with
O pneumonia (Carcas et al). 1999:65:245-50
Policosanol
omega-N-methylarginine policosanol in pI atients with typI e II hypI ercholesterolemia
Pharmacokinetics of the nitric oxide synthase inhibitor 1 additional coronary risk factors (Mas et al). 1999:65:439-47
> hydrochloride in pa Swith s ic shock (Hussein et Polymorphisms
999-65:1-9 Impact of genetic polymorphism > $,-adrenergic receptor on
Omeprazole s9ronchodilator pharmacodynamics (Lima et al
vitro SN
1 bilirubin glucuronidation i
1999-65:576-8
riSK : OTI
Oral contraceptives. Contraceptives, oral
Orange juice
Phenotypic
Prednisone
Oxaliplatin Phar
Ox
Oxybutynin Pregabalin
Pr
Progesterone
Phalidomide
jose pharmacokinetic ile
Prostaglandin endoperoxide synthase
Pain 1 demonstratior
1999-65
1999-65:653-60
Protein kinases
G-protein-coupled receptor kir
C 999-65:66 il 999-65:545-5
Pediatrics. sec Proto-oncogene proteins c-bcl-2
Pefloxacin nopril administration on blood bc/-2 concentrations i
Interac hn Of petioxacin and enoxacin with the human cytoc immunoglobulin A nephropathy (Buemi et al)
P450 enzyme CYP1A2 (Kinzig-Schippers et al). 1999;65 999:65:649-52
Pulmonary gas exchange
1 continu *rting enzyme inhibition facilitates alveolar-ca
hemodialysis and improves ventilation-perfusion coupling in
ventricular dysfunction (Guazzi et a ]
P-glycoprotein 1999-65
6’,7’-Dihydroxybergamottin
ce fects OI yClospor
ycoprotein (Edwards et a
Phenotype
I -genotype correlation tro SN-38 (active metabolite of Quinine
and bilirubin glucuronidation in human liver tissue with Quinine disposition in globally malnourished children with cerebral
promoter t ~orphis ret al). 1999:65:576-82 malaria (Pussard et al). 1999:65:500-10